Literature DB >> 11790232

T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study.

Rohit Bakshi1, Ralph H B Benedict, Robert A Bermel, Shelton D Caruthers, Srinivas R Puli, Christopher W Tjoa, Andrew J Fabiano, Lawrence Jacobs.   

Abstract

CONTEXT: While gray matter T2 hypointensity in multiple sclerosis (MS) has been associated with physical disability and clinical course, previous studies have relied on visual magnetic resonance imaging (MRI) assessments.
OBJECTIVE: To quantitatively determine if T2 hypointensity is associated with conventional MRI and clinical findings in MS.
DESIGN: Case-control study.
SETTING: University-affiliated community-based hospital.
SUBJECTS: Sixty patients with MS and 50 controls. MAIN OUTCOME MEASURES: T2 intensities of the substantia nigra, red nucleus, thalamus, putamen, globus pallidus, and caudate; third ventricular width; total brain T1 (hypointense) and T2 (hyperintense) lesion volumes; Expanded Disability Status Scale (physical disability) score; and disease course.
RESULTS: Deep gray matter T2 hypointensity was present in patients with MS in all structures (P<.005) except for the substantia nigra. T2 hypointensity was associated with third ventricle enlargement and higher T2 but not T1 plaque load. The regression model predicting third ventricle width included caudate T2 hypointensity (P =.006). The model predicting T2 lesion load included globus pallidus T2 hypointensity (P =.001). Caudate T2 hypointensity was the only variable associated with disability score in regression modeling (P =.03). All T2 hypointensities differentiated the secondary progressive from the relapsing-remitting clinical courses. The final model (P<.001) predicting clinical course retained T2 hypointensity of the thalamus, caudate, and putamen but not MRI plaques or atrophy.
CONCLUSIONS: Gray matter T2 hypointensity in MS is associated with brain atrophy and is a stronger predictor of disability and clinical course than are conventional MRI findings. While longitudinal studies are warranted, these results suggest that pathologic iron deposition is a surrogate marker of the destructive disease process.

Entities:  

Mesh:

Year:  2002        PMID: 11790232     DOI: 10.1001/archneur.59.1.62

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  62 in total

1.  Whole-brain atrophy in multiple sclerosis measured by automated versus semiautomated MR imaging segmentation.

Authors:  Jitendra Sharma; Michael P Sanfilipo; Ralph H B Benedict; Bianca Weinstock-Guttman; Frederick E Munschauer; Rohit Bakshi
Journal:  AJNR Am J Neuroradiol       Date:  2004 Jun-Jul       Impact factor: 3.825

2.  Extended haplotype analysis in the HLA complex reveals an increased frequency of the HFE-C282Y mutation in individuals with multiple sclerosis.

Authors:  Justin P Rubio; Melanie Bahlo; Niall Tubridy; Jim Stankovich; Rachel Burfoot; Helmut Butzkueven; Caron Chapman; Laura Johnson; Mark Marriott; Grant Mraz; Brian Tait; Chris Wilkinson; Bruce Taylor; Terence P Speed; Simon J Foote; Trevor J Kilpatrick
Journal:  Hum Genet       Date:  2004-03-11       Impact factor: 4.132

3.  Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity.

Authors:  Robert A Bermel; Srinivas R Puli; Richard A Rudick; Bianca Weinstock-Guttman; Elizabeth Fisher; Frederick E Munschauer; Rohit Bakshi
Journal:  Arch Neurol       Date:  2005-09

Review 4.  Pathogenic implications of iron accumulation in multiple sclerosis.

Authors:  Rachel Williams; Cassandra L Buchheit; Nancy E J Berman; Steven M LeVine
Journal:  J Neurochem       Date:  2011-11-11       Impact factor: 5.372

Review 5.  Imaging of multiple sclerosis: role in neurotherapeutics.

Authors:  Rohit Bakshi; Alireza Minagar; Zeenat Jaisani; Jerry S Wolinsky
Journal:  NeuroRx       Date:  2005-04

Review 6.  Magnetic resonance spectroscopy in the monitoring of multiple sclerosis.

Authors:  Ponnada A Narayana
Journal:  J Neuroimaging       Date:  2005       Impact factor: 2.486

7.  Toward a better understanding of brain lesions during metachromatic leukodystrophy evolution.

Authors:  A Martin; C Sevin; C Lazarus; C Bellesme; P Aubourg; C Adamsbaum
Journal:  AJNR Am J Neuroradiol       Date:  2012-04-26       Impact factor: 3.825

8.  Targeting Iron Dyshomeostasis for Treatment of Neurodegenerative Disorders.

Authors:  Niels Bergsland; Eleonora Tavazzi; Ferdinand Schweser; Dejan Jakimovski; Jesper Hagemeier; Michael G Dwyer; Robert Zivadinov
Journal:  CNS Drugs       Date:  2019-11       Impact factor: 5.749

Review 9.  MRI in multiple sclerosis: what's inside the toolbox?

Authors:  Mohit Neema; James Stankiewicz; Ashish Arora; Zachary D Guss; Rohit Bakshi
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

10.  Basal Ganglia Iron in Patients with Multiple Sclerosis Measured with 7T Quantitative Susceptibility Mapping Correlates with Inhibitory Control.

Authors:  P Schmalbrock; R S Prakash; B Schirda; A Janssen; G K Yang; M Russell; M V Knopp; A Boster; J A Nicholas; M Racke; D Pitt
Journal:  AJNR Am J Neuroradiol       Date:  2015-11-26       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.